The identification of oncogenic activation of particular tyrosine kinases (TKs) in some patients with advanced NSCLC in particular those mutations in epidermal growth factor receptor (EGFR) [10-12] have demonstrated that detection of such mutations in the plasma of newly diagnosed NSCLC patients is feasible [13], and led to the development of personalized medicine for these patients. The gene discussed is CDC42; the disease is non-small cell lung carcinoma.